SCHEMBL1884944

SCHEMBL1884944

COC(=O)c1cc(Cl)c(Cl)cc1N

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.64
ABL1 P00519 1/20 0.62
KDM4E B2RXH2 6/20 0.61
ALDH1A1 P00352 5/20 0.55
HSD17B10 Q99714 3/20 0.55
MAPT P10636 2/20 0.55
HPGD P15428 2/20 0.55
GLA P06280 2/20 0.55
CASP1 P29466 1/20 0.55
CASP7 P55210 1/20 0.55
ATM Q13315 1/20 0.55
TSHR P16473 2/20 0.51
ALOX15 P16050 1/20 0.51
NQO2 P16083 6/20 0.51
CFTR P13569 3/20 0.50
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7762378 0.90 ABL1 (0.61) GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL2897626 0.90 GAA (0.62) GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL17030839 0.87 ABL1 (0.57) GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL11922587 0.87 ABL1 (0.57) GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL19328721 0.86 GAA (0.72) GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL7853424 0.85 GAA (0.76) GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL19554228 0.85 ABL1 (0.56) GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL17384928 0.85 ABL1 (0.56) GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL18668513 0.85 GAA (0.57) GAAABL1KDM4EALDH1A1HSD17B10
SCHEMBL195076 0.85 GAA (0.57) GAAABL1KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 US disclosed
EP-4017593-B1 BICYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING SCRIPPS RESEARCH INST (US) 2025-07-23 EP disclosed
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO, INC. 2024-12-12 US disclosed
CN-118791407-A Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives 奥索生物公司 2024-10-18 CN disclosed
CN-115003383-B Bicyclic agonists of the interferon Gene stimulator STING 斯克里普斯研究学院 2024-10-01 CN disclosed
CN-118638096-A Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives 奥索生物公司 2024-09-13 CN disclosed
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2024-07-30 US disclosed
CN-112204008-B Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives 奥索生物公司 2024-07-05 CN disclosed
US-20230373940-A1 CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF KURES, INC. 2023-11-23 US disclosed
US-11787772-B2 Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-10-17 US disclosed
EP-1651622-A1 PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS Janssen Pharmaceutica N.V. (BE) 2006-05-03 EP disclosed
EP-1651621-A1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-03 EP disclosed
EP-1650190-A1 3-aryl-3-methyl-quinoline-2,4-diones, preparation method thereof and pharmaceutical composition containing same Korea Research Institute of Chemical Technology (KR) 2006-04-26 EP disclosed
US-20060084676-A1 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2006-04-20 US disclosed
WO-2006036670-A1 SULFONAMIDE COMPOUNDS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-04-06 WO disclosed
US-20060069286-A1 Sulfonamide compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2006-03-30 US disclosed
US-20050043310-A1 Preparation of quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 US disclosed
WO-2005016896-A1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 WO disclosed
WO-2005016897-A1 PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 WO disclosed
US-20050038032-A1 Quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787772-B2 Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists OPRD1, OPRM1, OPRK1 GAA 2298/4885ABL1 2514/4885KDM4E 1278/4885
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B GAA 838/4885ABL1 394/4885KDM4E 3158/4885
US-20050043310-A1 Preparation of quinoxaline compounds CCKAR, CCKBR, GIPR GAA 1615/4885ABL1 1011/4885KDM4E 3167/4885
US-20230373940-A1 CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF CDKL5, KMT5A, CDKL1 GAA 2250/4885ABL1 864/4885KDM4E 126/4885
US-20060084676-A1 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same HTR6, HTR3B, HTR2C GAA 3223/4885ABL1 483/4885KDM4E 1103/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 GAA 2559/4885ABL1 2031/4885KDM4E 3921/4885
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B GAA 838/4885ABL1 394/4885KDM4E 3158/4885
US-20050038032-A1 Quinoxaline compounds CCKAR, CCKBR, GIPR GAA 1879/4885ABL1 763/4885KDM4E 3681/4885
US-20060069286-A1 Sulfonamide compounds CCKAR, CCKBR, TAS1R2 GAA 3425/4885ABL1 1777/4885KDM4E 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.